

Section: Contact Information

First Name : **Olatundun**

Last Name : **Williams**

Institution : **Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine**

Address 1 : **225 E. Chicago Avenue**

Address 2 :

City : **Chicago**

State/Province/Region : **IL**

Country : **US**

Zip/Postal Code : **60611**

Phone Number : **3122275090**

Alternate Phone Number :

Email Address : owilliams@luriechildrens.org

Section: Project Requirements and Description

Group: Requirements to submit AOI

A comprehensive review of previously published data has been completed. : **Yes**

The specific aims are clear and focused. : **Yes**

The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator. : **Yes**

The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months. : **Yes**

Project Title : **Long-term morbidity in survivors of childhood CML**

Planned research population (eligibility criteria) :

Survivors of CML (76 patients from the original cohort and 72 patients from the expansion cohort)

Proposed specific aims :

1) Quantify the incidence of late effects in childhood CML survivors 2) Evaluate the risk factors for morbidities in survivors of childhood CML 3) Compare morbidity in childhood CML survivors between the original and expansion cohorts 4) Compare morbidity in childhood CML survivors with the general survivor population

Will the project require non-CCSS funding to complete? : **No**

If yes, what would be the anticipated source(s) and timeline(s) for securing funding? :

Group: Does this project require contact of CCSS study subjects for:

Additional self-reported information : **No**

Biological samples : **No**

Medical record data : **No**

If yes to any of the above, please briefly describe. :

Group: What CCSS Working Group(s) would likely be involved? (Check all that apply)

Second Malignancy : **Secondary**

Chronic Disease : **Primary**

Psychology / Neuropsychology : **Secondary**

Genetics :

Cancer Control :

Epidemiology / Biostatistics : **Secondary**

Section: Outcomes or Correlative Factors

Late mortality : **Primary**

Second Malignancy : **Primary**

Group: Health Behaviors

Tobacco : **Secondary**

Alcohol : **Secondary**

Physical activity : **Secondary**

Medical screening : **Secondary**

Other :

If other, please specify :

Group: Psychosocial

Insurance : **Secondary**

Marriage : **Secondary**

Education : **Secondary**

Employment : **Secondary**

Other :

If other, please specify :

Group: Medical Conditions

Hearing/Vision/Speech : **Primary**

Hormonal systems : **Primary**

Heart and vascular : **Primary**

Respiratory : **Primary**

Digestive : **Primary**

Surgical procedures : **Primary**

Brain and nervous system : **Primary**

Other :

If other, please specify :

Group: Medications

Describe medications :

Group: Psychologic/Quality of Life

BSI-18 : **Secondary**

SF-36 : **Secondary**

CCSS-NCQ : **Secondary**

PTS : **Secondary**

PTG : **Secondary**

Other :

If other, please specify :

Group: Other

Pregnancy and offspring : **Primary**

Family history : **Secondary**

Chronic conditions (CTCAE v3) :

Health status :

Group: Demographic

Age : **Primary**

Race : **Primary**

Sex : **Primary**

Other :

If other, please specify :

Group: Cancer treatment

Chemotherapy : **Correlative Factors**

Radiation therapy : **Correlative Factors**

Surgery :

Section: Anticipated Sources of Statistical Support

CCSS Statistical Center : **Yes**

Local institutional statistician :

If local, please provide the name(s) and contact information of the statistician(s) to be involved. :

Will this project utilize CCSS biologic samples? : **No**

If yes, which of the following? :

If other, please explain :

Section: Other General Comments

Other General Comments :

We acknowledge the population is small, but there are very few studies that reported long-term morbidity in children with CML. The proposed study will add valuable information. The plan was discussed with Dr. Greg Armstrong. Dr. Nobuko Hijiya will be my mentor/senior co-investigator for this study.